RDB08257 - CSIV-CMV-MCS-IRES2-Venus

CSIV-CMV-MCS-IRES2-Venus (#RDB08257)

Backbone vector plasmid of lentivirus construct driven by CMV promoter with Venus fluorescent protein marker.

Drawn by SnapGene® software

Sequence information (Assembled from experimentally sequenced data)	GenBank Flat File Format open
	SnapGene file download
Publication	Unpublished bioresource
Test sheet	Data Sheet open

Clone info.	Backbone vector plasmid of lentivirus construct driven by CMV promoter with Venus fluorescent protein marker.
Comment	pCMV-VSV-G-RSV-Rev (RDB04393) and pCAG-HIVgp (RDB04394) are popular choices for lentivirus packaging.
Selectable markers	Ampicillin (E. coli). Please note that Zeo resistance marker is not included in the lentivirus produced from this vector.
Depositor\|Developer	Miyoshi, Hiroyuki \|

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.

Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
Please visit Ordering instruction.[link]

Terms and conditions for distribution The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit academic purpose. The RECIPIENT agrees to expressly describe the late Dr. Hiroyuki Miyoshi as the Developer.
Additional terms and conditions:
When publishing the results obtained using the BIOLOGICAL RESOURCE, a citation of literature specified by Dr. Atsushi Miyawaki or an acknowledgement to Dr. Miyawaki is requested.
Nagai, T. et al., Nat. Biotechnol. 20: 87-90 (2002).

Further transfer, provision of services or resale of the Zeocin resistance gene, and the Deposited Materials is prohibited without InvivoGen's prior written consent. In addition, InvivoGen's Limited Use Label License applies to your use of this product.

Remarks ((Remarks)) Remember that you will be working with samples containing infectious virus.
Please contact us. We will provide you with appropriate documents.
Zeocin® is a trademark of InvivoGen registered with the United States Patent and Trademark Office and foreign equivalents. See InvivoGen Limited Use Label License.

提供案内 (日本国内) [open/close]

Ordering forms	Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ] MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ] Please visit Ordering instruction.[link]
Terms and conditions for distribution	The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit academic purpose. The RECIPIENT agrees to expressly describe the late Dr. Hiroyuki Miyoshi as the Developer. Additional terms and conditions: When publishing the results obtained using the BIOLOGICAL RESOURCE, a citation of literature specified by Dr. Atsushi Miyawaki or an acknowledgement to Dr. Miyawaki is requested. Nagai, T. et al., Nat. Biotechnol. 20: 87-90 (2002). Further transfer, provision of services or resale of the Zeocin resistance gene, and the Deposited Materials is prohibited without InvivoGen's prior written consent. In addition, InvivoGen's Limited Use Label License applies to your use of this product.
Remarks	((Remarks)) Remember that you will be working with samples containing infectious virus. Please contact us. We will provide you with appropriate documents. Zeocin® is a trademark of InvivoGen registered with the United States Patent and Trademark Office and foreign equivalents. See InvivoGen Limited Use Label License.

必要書類	提供依頼書 [依頼書の記入例 ] 提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ] 手続きの概要は、「レンチウイルスベクターの提供申し込み」をご覧ください。
MTAに書く使用条件	本件研究材料は、非営利機関の非営利学術研究に限って提供する。本件研究材料を利用した研究結果等を発表する際は、本件研究材料が故三好浩之博士により開発されたことを明示する。付加的使用条件： When publishing the results obtained using the BIOLOGICAL RESOURCE, a citation of literature specified by Dr. Atsushi Miyawaki or an acknowledgement to Dr. Miyawaki is requested. Nagai, T. et al., Nat. Biotechnol. 20: 87-90 (2002). InvivoGen社の事前の書面による同意がない限り、ゼオシン耐性遺伝子および寄託マテリアルの第三者への移転、サービスの提供、または再販売は禁止されています。また、ご利用に際してInvivoGen社のLimited Use Label Licenseが適用されます。
備考	【使用上の注意】このリソースはウイルス粒子産生用のため、取扱いに注意が必要です。 ZeocinはInvivoGen社の製品です。Zeocin®は、米国特許商標庁および米国外の同等機関に登録されたInvivoGen社の商標です。InvivoGen Limited Use Label Licenseをご確認ください。

Catalog #	Resource name	Shipping form	Fee
RDB08257	CSIV-CMV-MCS-IRES2-Venus	Please contact us.

Ordering instruction of plasmids [in Japanese] [in English]

How to cite this biological resource

Materials & Methods section:

The CSIV-CMV-MCS-IRES2-Venus was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB08257).

Reference section:

Further references such as user reports and related articles (go to bottom)

References

Original, user report and related articles

user_report	Ichikawa, D., Integrated diagnosis based on transcriptome analysis in suspected pediatric sarcomas. NPJ Genom. Med. 6(1): 49 (2021). PMID 34131151. [PubMed] [Article] [RRC of NBRP]
user_report	Hirota, A., The nucleosome remodeling and deacetylase complex protein CHD4 regulates neural differentiation of mouse embryonic stem cells by down-regulating p53. J. Biol. Chem. 294 (1): 195-209 (2019). PMID 30409903. [PubMed] [Article] [RRC of NBRP]
user_report	Fujimoto, S., KLF4 prevents epithelial to mesenchymal transition in human corneal epithelial cells via endogenous TGF-beta2 suppression. Regen. Ther. 11: 249-257 (2019). PMID 31538102. [PubMed] [Article] [RRC of NBRP]
user_report	Suzuki, K., MEF2D-BCL9 Fusion Gene Is Associated With High-Risk Acute B-Cell Precursor Lymphoblastic Leukemia in Adolescents. J. Clin. Oncol. 34 (28): 3451-3459 (2016). PMID 27507882. [PubMed] [Article] [RRC of NBRP]
user_report	Yamaguchi, S., Characterization of common marmoset dysgerminoma-like tumor induced by the lentiviral expression of reprogramming factors. Cancer Sci. 105 (4): 402-408 (2014). PMID 24521492. [PubMed] [Article] [RRC of NBRP]

Resource search

Link

Other resources in our bank

External Database

Reference sequence